BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 28230018)

  • 1. The significance of transarterial chemoembolization combined with systemic chemotherapy for patients with KRAS wild-type unresectable metachronous colorectal carcinoma with liver metastases.
    Yu Q; Zhang L; Fan S; Huang L; Wang X; Xindun C
    J Cancer Res Ther; 2016 Dec; 12(Supplement):C205-C211. PubMed ID: 28230018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases.
    Ye LC; Liu TS; Ren L; Wei Y; Zhu DX; Zai SY; Ye QH; Yu Y; Xu B; Qin XY; Xu J
    J Clin Oncol; 2013 Jun; 31(16):1931-8. PubMed ID: 23569301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transarterial chemoembolization of unresectable systemic chemotherapy-refractory liver metastases from colorectal cancer: long-term results over a 10-year period.
    Gruber-Rouh T; Naguib NN; Eichler K; Ackermann H; Zangos S; Trojan J; Beeres M; Harth M; Schulz B; Nour-Eldin A NE; Vogl TJ
    Int J Cancer; 2014 Mar; 134(5):1225-31. PubMed ID: 23960002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combining systemic chemotherapy with chemoembolization in the treatment of unresectable hepatic metastases from colorectal cancer.
    You YT; Changchien CR; Huang JS; Ng KK
    Int J Colorectal Dis; 2006 Jan; 21(1):33-7. PubMed ID: 15942741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Up-front systemic chemotherapy is a feasible option compared to primary tumor resection followed by chemotherapy for colorectal cancer with unresectable synchronous metastases.
    Niitsu H; Hinoi T; Shimomura M; Egi H; Hattori M; Ishizaki Y; Adachi T; Saito Y; Miguchi M; Sawada H; Kochi M; Mukai S; Ohdan H
    World J Surg Oncol; 2015 Apr; 13():162. PubMed ID: 25908502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conversion to complete resection with mFOLFOX6 with bevacizumab or cetuximab based on K-ras status for unresectable colorectal liver metastasis (BECK study).
    Hatano E; Okuno M; Nakamura K; Ishii T; Seo S; Taura K; Yasuchika K; Yazawa T; Zaima M; Kanazawa A; Terajima H; Kaihara S; Adachi Y; Inoue N; Furumoto K; Manaka D; Tokka A; Furuyama H; Doi K; Hirose T; Horimatsu T; Hasegawa S; Matsumoto S; Sakai Y; Uemoto S
    J Hepatobiliary Pancreat Sci; 2015 Aug; 22(8):634-45. PubMed ID: 25926024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conventional transarterial chemoembolization combined with systemic therapy versus systemic therapy alone as second-line treatment for unresectable colorectal liver metastases: randomized clinical trial.
    Liu Y; Chang W; Zhou B; Wei Y; Tang W; Liang F; Chen Y; Yan Z; Lv M; Ren L; Xu J
    Br J Surg; 2021 Apr; 108(4):373-379. PubMed ID: 33611431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histological response, pattern of tumor destruction and clinical outcome after neoadjuvant chemotherapy including bevacizumab or cetuximab in patients undergoing liver resection for colorectal liver metastases.
    Stremitzer S; Stift J; Singh J; Starlinger P; Gruenberger B; Tamandl D; Gruenberger T
    Eur J Surg Oncol; 2015 Jul; 41(7):868-74. PubMed ID: 25865557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical efficacy of postoperative adjuvant transcatheter arterial chemoembolization on hepatocellular carcinoma.
    Liu C; Sun L; Xu J; Zhao Y
    World J Surg Oncol; 2016 Apr; 14():100. PubMed ID: 27038790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic analysis of transarterial chemoembolization combined with a traditional Chinese herbal medicine formula for treatment of unresectable hepatocellular carcinoma.
    Yu Y; Lang QB; Chen Z; Li B; Yu CQ; Zhu DZ; Huang XQ; Zhai XF; Ling CQ
    Chin Med J (Engl); 2009 Sep; 122(17):1990-5. PubMed ID: 19781383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transarterial chemoembolization with raltitrexed-based or floxuridine-based chemotherapy for unresectable colorectal cancer liver metastasis.
    Wei N; Zhang B; Wang Y; He XH; Xu LC; Li GD; Wang YH; Wang GZ; Huang HZ; Li WT
    Clin Transl Oncol; 2019 Apr; 21(4):443-450. PubMed ID: 30306400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overall survival after transarterial lipiodol infusion chemotherapy with or without embolization for unresectable hepatocellular carcinoma: propensity score analysis.
    Takayasu K; Arii S; Ikai I; Kudo M; Matsuyama Y; Kojiro M; Makuuchi M;
    AJR Am J Roentgenol; 2010 Mar; 194(3):830-7. PubMed ID: 20173167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant TACE before laser induced thermotherapy (LITT) in the treatment of non-colorectal non-breast cancer liver metastases: feasibility and survival rates.
    Vogl TJ; Kreutzträger M; Gruber-Rouh T; Eichler K; Nour-Eldin NE; Zangos S; Naguib NN
    Eur J Radiol; 2014 Oct; 83(10):1804-10. PubMed ID: 25082479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of hepatic resection and transarterial chemoembolization for solitary hepatocellular carcinoma.
    Zhang DZ; Wei XD; Wang XP
    World J Gastroenterol; 2015 Apr; 21(15):4635-43. PubMed ID: 25914473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome of patients with colorectal liver metastasis: analysis of 1,613 consecutive cases.
    Dexiang Z; Li R; Ye W; Haifu W; Yunshi Z; Qinghai Y; Shenyong Z; Bo X; Li L; Xiangou P; Haohao L; Lechi Y; Tianshu L; Jia F; Xinyu Q; Jianmin X
    Ann Surg Oncol; 2012 Sep; 19(9):2860-8. PubMed ID: 22526903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Large primary hepatocellular carcinoma: transarterial chemoembolization monotherapy versus combined transarterial chemoembolization-percutaneous microwave coagulation therapy.
    Xu LF; Sun HL; Chen YT; Ni JY; Chen D; Luo JH; Zhou JX; Hu RM; Tan QY
    J Gastroenterol Hepatol; 2013 Mar; 28(3):456-63. PubMed ID: 23216261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intra-arterial infusion of 5-fluorouracil plus granulocyte-macrophage colony-stimulating factor (GM-CSF) and chemoembolization with melphalan in the treatment of disseminated colorectal liver metastases.
    Müller H; Nakchbandi W; Chatzissavvidis I; Valek V
    Eur J Surg Oncol; 2001 Nov; 27(7):652-61. PubMed ID: 11669594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical efficacy of liver resection after downsizing systemic chemotherapy for initially unresectable liver metastases.
    Kawamura J; Yazawa T; Sumida K; Kida Y; Ogawa R; Tani M; Kawasoe J; Yamamoto M; Harada H; Yamamoto H; Zaima M
    World J Surg Oncol; 2016 Feb; 14():56. PubMed ID: 26911142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repetitive transarterial chemoembolization (TACE) of liver metastases from gastric cancer: local control and survival results.
    Vogl TJ; Gruber-Rouh T; Eichler K; Nour-Eldin NE; Trojan J; Zangos S; Naguib NN
    Eur J Radiol; 2013 Feb; 82(2):258-63. PubMed ID: 23127803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-EGF Receptor-Based Conversion Chemotherapy in RAS Wild-Type Colorectal Cancer Patients: Impact on Survival and Resection Rates.
    Koch C; Schmidt N; Winkelmann R; Eichler K; Pession U; Bechstein WO; Zeuzem S; Waidmann O; Trojan J
    Digestion; 2018; 98(4):263-269. PubMed ID: 30130797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.